Search clinical trials for: EGFR C797s

Total 1599 results

Yonsei University

Not yet recruiting

Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib (LUCAS)

Non-small Cell Lung Cancer

Korea, Republic of
Janux Therapeutics

Recruiting

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Renal Cell Carcinoma | Non-Small Cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Colorectal Carcinoma

United States
Kezar Life Sciences, Inc.

Recruiting

A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)

Lupus Nephritis

United States, Korea, Republic of, Australia, Malaysia, Taiwan, South Africa, China, Singapore, United Kingdom, Puerto Rico, Croatia, India, Greece, Spain, Brazil, Philippines, Guatemala, Argentina, Portugal, Colombia
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

NSCLC | EGFR Activating Mutation | Anlotinib | TP53 | Aumolertinib
The First Affiliated Hospital of Guangzhou Medical...

Recruiting

Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

Non-small Cell Lung Cancer

China
National Cancer Centre, Singapore
Taiho Pharmaceutical Co., Ltd.

Recruiting

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

NSCLC

Singapore
Seattle Children's Hospital

Recruiting

Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors

Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma | Refractory Primary Malignant Central Nervous System Neoplasm | Recurrent CNS Tumor, Adult | Recurrent, CNS Tumor, Childhood

United States
Suzhou Puhe Pharmaceutical Technology Co., LTD

Not yet recruiting

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

China
Sun Yat-sen University

Recruiting

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Brain Metastases | Radiotherapy | EGFR Activating Mutation

China
Suzhou Puhe Pharmaceutical Technology Co., LTD

Recruiting

Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR

Treatment Side Effects | Treatment

China
The Second Affiliated Hospital of Shandong First...

Recruiting

Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.

Non-small Cell Lung Cancer

China
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN (APPARENT)

IC-MPGN

France, Germany, Spain, Switzerland, Japan, United States, Canada, India, United Kingdom, Israel, Brazil, Turkey, Italy, Vietnam, Argentina, Czechia, Poland
Shanghai Chest Hospital
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients

Non-squamous NSCLC

China
Fourth Affiliated Hospital of Guangxi Medical University
Guilin Medical University, China; Wuzhou Red Cross Hospital; Second Affiliated... and other collaborators

Recruiting

Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma by AJCC V8 Stage

China
Pusan National University Hospital
Yuhan Corporation

Not yet recruiting

Impact of Lazertinib Dose Modification on Effectiveness and Safety

Non-small Cell Lung Cancer

Korea, Republic of
DEKA Biosciences

Recruiting

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Kidney Cancer | Cancer | Head and Neck Cancer | Gynecologic Cancer | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Skin Cancer | Pancreas Cancer

United States
Samsung Medical Center

Not yet recruiting

Lazertinib 160mg in EGFR T790M NSCLC

Lung Cancer Stage IV | EGFR T790M

Korea, Republic of
Nir Peled

Not yet recruiting

A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC

Non Small Cell Lung Cancer | EGFR Gene Mutation | Immune Checkpoint Inhibitor

Israel
Australasian Gastro-Intestinal Trials Group
Olivia Newton-John Cancer Research Institute

Recruiting

Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Australia
Shanghai Miracogen Inc.

Recruiting

A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors

Advanced Solid Tumors

China
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

NSCLC, Stage I

China
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Non Small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Non Small Cell Lung Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

Richter Syndrome | Recurrent Transformed Chronic Lymphocytic Leukemia | Refractory Transformed Chronic Lymphocytic Leukemia

United States
Fujian Cancer Hospital

Not yet recruiting

Almonertinib Plus Metronomic Oral Vinorelbine

NSCLC | EGFR | Third-generation TKI
West China Hospital

Recruiting

Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

Non-small Cell Lung Cancer

China
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Hoth Therapeutics, Inc.
Worldwide Clinical Trials

Recruiting

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors (CLEER)

Acneiform Eruption Due to Chemical | Xerosis Cutis | Paronychia

United States
SWOG Cancer Research Network
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Grade 3b Follicular Lymphoma | Transformed Follic Lymph to Diff Large B-Cell Lymphoma | Transformed Marg Zone Lymph to Diff...

United States
Mandana Kamgar, MD

Recruiting

A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy

Pancreatic Ductal Adenocarcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Primary Central Nervous System Lymphoma

Central Nervous System Lymphoma

United States
Sun Yat-sen University

Not yet recruiting

Combination of Local Therapy and Target Therapy for Brain Metastases With EGFR Mutation (CLTBME)

Brain Metastases
ArriVent BioPharma, Inc.
Allist Pharmaceuticals, Inc.

Recruiting

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | EGFR Exon 20 Mutations

United States, Australia, Spain, France, Italy, China, Japan, Korea, Republic of, Malaysia, Netherlands, Philippines, Singapore, Taiwan, Thailand, Brazil, Israel, United Kingdom, Mexico
ETOP IBCSG Partners Foundation
Janssen Pharmaceuticals

Recruiting

AMAZE-lung: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI (AMAZE-lung)

Non Small Cell Lung Cancer

Spain, France, Switzerland, United Kingdom, Singapore, Italy, Netherlands
Second Xiangya Hospital of Central South University
The First Affiliated Hospital of Nanchang University; Xiangya Hospital of Central... and other collaborators

Recruiting

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study) (PRECISE)

Lung Cancer, Non-small Cell | Circulating Tumor DNA | EGFR Gene Mutation | EGFR-TKI Resistant Mutation | Primary Resistance

China
Dragonfly Therapeutics
Merck Sharp & Dohme LLC

Recruiting

Study of DF9001 in Patients With Advanced Solid Tumors

Solid Tumor, Adult

United States
Mirati Therapeutics Inc.

Recruiting

A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

Solid Tumor | Non Small Cell Lung Cancer | Advanced Solid Tumor | Colo-rectal Cancer

United States, Puerto Rico
Affiliated Hospital of Jiangnan University

Recruiting

Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | EGF-R Positive Non-Small Cell Lung Cancer

China
Peking Union Medical College Hospital
Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Recruiting

Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15) (WU-KONG15)

Non Small Cell Lung Cancer

China
Qilu Pharmaceutical Co., Ltd.

Recruiting

To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation

Non-small Cell Lung Cancer

China
RedCloud Bio
R&G Pharma Studies Co.,Ltd.

Recruiting

H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC

Non-small Cell Lung Cancer

China
AstraZeneca

Recruiting

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

Non-small Cell Lung Cancer

China
Chongqing University Cancer Hospital
Army Specialty Medical Center; The Second Affilicated Hospital of Chongqing...

Recruiting

First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

Non-small Cell Lung Cancer | EGFR G719X | EGFR L861Q | EGFR S768I

China
Guangdong Association of Clinical Trials

Recruiting

Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC

MRD

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC

Non-small Cell Lung Cancer
Jun Liu

Recruiting

A Single-arm Exploratory Study of Neoadjuvant Therapy

Lung Adenocarcinoma

China
Samsung Medical Center

Recruiting

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

Lung Adenocarcinoma

Korea, Republic of
AstraZeneca

Recruiting

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (TARGET)

Stage II-IIIB Non-small Cell Lung Carcinoma

Spain, Korea, Republic of, Philippines, Italy, United States, Malaysia, Taiwan, Thailand, Hong Kong, United Kingdom, Singapore
National Cancer Institute (NCI)

Not yet recruiting

Study to Determine Possible Effects of Apalutamide on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Urothelial Carcinoma | Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
RedCloud Bio
Parexel

Recruiting

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

Non-small Cell Lung Cancer

United States
Pusan National University Hospital

Recruiting

Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer

Non Small Cell Lung Cancer | EGFR Gene Mutation

Korea, Republic of

Search clinical trials for: EGFR C797s

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations